Assessing changes in relapse rates in multiple sclerosis. - Wikidata - awgldk - TriplyDB

Assessing changes in relapse rates in multiple sclerosis.

Assessing changes in relapse rates in multiple sclerosis.

http://www.wikidata.org/entity/Q33681680

about

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Development of oral immunomodulatory agents in the management of multiple sclerosis Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review.Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.Risk stratification and mitigation multiple sclerosis.Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.Randomized study combining interferon and glatiramer acetate in multiple sclerosis Venous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients.Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.Statistical cures and other fallacies.Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis.Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.Can we measure long-term treatment effects in multiple sclerosis?Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS.Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.Time to first relapse as an endpoint in multiple sclerosis clinical trials.Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.Sample Size Estimation for Negative Binomial Regression Comparing Rates of Recurrent Events with Unequal Follow-Up Time.Defining and scoring response to IFN-β in multiple sclerosis.Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

P2860

Q24187126-5F4F75C2-AF55-462B-A7EA-ACABB857F097 Q24188270-6BFA41F4-8E13-4FA2-B0AE-C0126242CBDA Q26798434-1F836107-5C1D-4FFD-9FA9-28755CF859F7 Q26852672-3B37B249-3F6C-4CF7-9F66-64226261E4CD Q26998513-19C5EB17-B74A-441F-9B52-D7CDECFB9F87 Q28388704-4CE431FA-8FF6-4EAC-88A5-78669800D086 Q30000824-8AA6C59B-98CC-4B66-B331-B85A528BAD50 Q33634866-8A71FC44-BB2A-4887-B82C-1760CD8FA095 Q33931512-17B8AFF2-27D2-4B63-858A-1C27D686A06B Q34045441-EF6C28EE-B495-40B7-936E-31BCDB89ABBC Q34155446-2972D346-4F68-4843-8364-DBC561A5123C Q34729752-1C9149A7-2EB0-4FA4-B208-A61C623FFC88 Q35649734-DDBDF0EF-A807-4AE1-92B8-34AA551D8F22 Q35761200-3BC6A4CB-5E98-488E-9899-EFC00736DB16 Q36780801-2B66703E-1F6F-44B4-BCBD-4333F4024079 Q37267207-32C3F018-A2F8-40F6-9A37-5732872A169E Q37876566-620C0B89-F392-455E-85B3-EBF15A0FB0F0 Q37964985-7FC4BD28-5E8A-43B9-AA45-09943285ACBE Q37987082-7DC213B0-BCA2-4923-9301-46A7C29E23BA Q37994162-68BD2449-1B17-47AA-A18E-0F00CF56C7B0 Q38087504-D74853D5-8123-4605-BD34-CEC85A5FAAD1 Q38298427-10F36683-F646-40DB-A961-5D9C336D1FF9 Q38375605-084B0DC6-1624-40DA-9F6D-18E1BDC99DDD Q39024650-B50665CA-47CF-487D-B745-8BF2E87A6FCD Q39300217-6BA14C54-CD34-4D6B-96C1-84116759AB5A Q39565012-CF720EB4-787C-455B-A16C-F7574503B5EC Q45108872-65E9A75F-28FC-4F74-B90D-9854D87C9959 Q45218637-E6AB0E37-4063-469C-9C36-CD40F6D06D6A Q46023940-8077525F-79FB-4FC7-BE45-53F76DB539EA Q47327274-2C166DBC-6D35-4CCB-AB4A-336D6DAF551F Q48922719-E4B39A07-39D5-46B9-A4B2-CD21F85A062C

P2860

Assessing changes in relapse rates in multiple sclerosis.

http://www.wikidata.org/entity/Q33681680

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Assessing changes in relapse rates in multiple sclerosis.

@ast

Assessing changes in relapse rates in multiple sclerosis.

@en

type

label

Assessing changes in relapse rates in multiple sclerosis.

@ast

Assessing changes in relapse rates in multiple sclerosis.

@en

prefLabel

Assessing changes in relapse rates in multiple sclerosis.

@ast

Assessing changes in relapse rates in multiple sclerosis.

@en

P1433

Q33681680-7E5344CB-59CD-4950-8438-C6E2DAD13E3E

P1476

Q33681680-30F6F45A-4F62-4609-98FC-547C163E23CA

P2093

Q33681680-11B199D2-F9F5-4880-AF03-84ADE6B8F072

Q33681680-280578B8-54E2-414B-B9B8-39930ADE6CC2

Q33681680-3647C04E-AA21-4B8F-937D-A6E3A00F28BE

Q33681680-3E30ED72-AFF4-4DB5-AD86-4B162F5FC57E

Q33681680-70A2DDDB-0F84-4CBB-922C-506A3A382367

Q33681680-81A952CB-0115-45F9-845B-5086D921DBA0

Q33681680-DB9EC07A-DB42-435B-AD43-59DD5EF5F5F9

P2860

Q33681680-00742236-673D-4E70-9442-18F43719D96F

Q33681680-0B7270B1-4BA4-4D5B-86F4-35E9BBFD070F

Q33681680-10331253-AE49-493F-941A-562724B4350C

Q33681680-11868D9D-E34C-48F2-B200-F5B0EFA86A12

Q33681680-14C570BA-C02B-4AC3-BF16-35ADA051027F

Q33681680-18E0324F-9066-42E4-A01B-F7CBD377CF60

Q33681680-1F970AB0-94FA-462B-80D8-2626F0FF75DB

Q33681680-2071056D-0EC2-4450-8E37-43CE1382F526

Q33681680-22DD5350-AD99-4692-BD5A-D36DE5629513

Q33681680-36BE0426-8679-4854-9A42-04299A0FE859

P304

Q33681680-3387ACEF-69B7-4CC5-97BB-E9B42D85598B

P31

Q33681680-5A4167D4-6CBA-48E9-A27D-A36CD82F31CE

P356

Q33681680-B247EF35-6702-4235-9F42-12C6E4310A3A

P433

Q33681680-EFBB6AAD-938D-4E53-A01C-21103517BB68

P478

Q33681680-F4DF916D-12E8-43DD-9999-15E8AC4277A8

P577

Q33681680-04BF0166-DF3D-461A-87E9-664C052A67C7

P5875

Q33681680-4A63B904-AFB9-4150-AC90-0F7E11312F80

P698

Q33681680-700DEFB3-1863-4497-9D53-CF3BAA48AA10

P921

Q33681680-50ECCB7B-0C1B-4A99-95F5-971FF0DCF818

P356

1352458510379246

P1433

Multiple Sclerosis Journal

P1476

Assessing changes in relapse rates in multiple sclerosis.

@en

P2093

Gary R Cutter

http://www.w3.org/2001/XMLSchema#string

Inmaculada B Aban

http://www.w3.org/2001/XMLSchema#string

Maria P Sormani

http://www.w3.org/2001/XMLSchema#string

Seidu Inusah

http://www.w3.org/2001/XMLSchema#string

Solomon K Musani

http://www.w3.org/2001/XMLSchema#string

Stacey S Cofield

http://www.w3.org/2001/XMLSchema#string

Vinodh Srinivasasainagendra

http://www.w3.org/2001/XMLSchema#string

P2860

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

P304

1414-1421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458510379246

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46110235

http://www.w3.org/2001/XMLSchema#string

P698

20810517

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis